Joe Talamo is chief financial officer at HiberCell. He has more than 25 years of biotechnology industry experience in publicly-traded, development and commercial stage companies with expertise in capital fund raising activities and merger and acquisition transactions. Prior to joining HiberCell, Joe served as the chief financial officer of Caladrius Biosciences, Inc., where he led initiatives to raise over $150 million to fund the company’s operations, including numerous private and public offerings, and the divestiture of its contract manufacturing subsidiary. Joe also held various senior financial positions at OSI Pharmaceuticals, Inc., which was acquired by Astellas in 2010, most recently serving as its vice president and corporate controller where he helped build the accounting and finance infrastructure to support the clinical development and commercial launch of Tarceva®. Joe began his career at KPMG in the Health Care and Life Sciences Audit Group, and currently serves as treasurer of the Cura Foundation, a public charity dedicated to raising awareness about adult stem cells and their therapeutic promise.
Joe received a B.B.A in accounting and an MBA in finance from Hofstra University. He is a certified public accountant in the State of New York.